- Open
- 0.60
- High
- 0.65
- Low
- 0.61
- Close
- 0.61
- Change
- +0.00 (0.00%)
- Volume
- 1,664,478
| 29 Sept 2026 | 07:24:01 | New Patent Granted for miRisten in China |
| 25 Sept 2026 | 07:00:06 | RNA gene-silencing cardiovascular program advances |
| 15 Sept 2026 | 07:00:06 | Business Update and Notice of Results |
| 4 Aug 2026 | 10:30:00 | Holding(s) in Company |
| 31 Jul 2026 | 11:07:26 | Total Voting Rights |
| 9 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 30 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
Thalia Therapeutics PLC is a holding company for N4 UK and Nanogenics, providing funding for their operations. N4 UK develops nanoparticle silica delivery systems to enhance the delivery and effectiveness of cancer treatments and vaccines. Nanogenics focuses on a Liptide® platform for delivering proprietary siRNA sequences to silence fibrotic genes. The company is advancing a pipeline of RNA-based therapeutics, particularly targeting cardiovascular diseases, while also exploring gene therapy candidates for glaucoma.
| 29 Sept 2026 | 07:24:01 | New Patent Granted for miRisten in China |
| 25 Sept 2026 | 07:00:06 | RNA gene-silencing cardiovascular program advances |
| 15 Sept 2026 | 07:00:06 | Business Update and Notice of Results |
| 4 Aug 2026 | 10:30:00 | Holding(s) in Company |
| 31 Jul 2026 | 11:07:26 | Total Voting Rights |
| 9 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 30 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
Thalia Therapeutics PLC is a holding company for N4 UK and Nanogenics, providing funding for their operations. N4 UK develops nanoparticle silica delivery systems to enhance the delivery and effectiveness of cancer treatments and vaccines. Nanogenics focuses on a Liptide® platform for delivering proprietary siRNA sequences to silence fibrotic genes. The company is advancing a pipeline of RNA-based therapeutics, particularly targeting cardiovascular diseases, while also exploring gene therapy candidates for glaucoma.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £301m | -0.1% | |
| £43m | -0.2% | |
| £32m | — | |
| £12m | +4.3% | |
| £11m | +0.3% | |
THATThalia Therapeutics PLC | £11m | -0.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £301m | -0.1% | |
| £43m | -0.2% | |
| £32m | — | |
| £12m | +4.3% | |
| £11m | +0.3% | |
THATThalia Therapeutics PLC | £11m | -0.1% |